Criteria for assessing evidence for biomarker-targeted therapies in rare cancers—an extrapolation framework.

MLA

Cho, Doah, et al. “Criteria for Assessing Evidence for Biomarker-Targeted Therapies in Rare Cancers—an Extrapolation Framework.” Therapeutic Advances in Medical Oncology, Sept. 2024, pp. 1–20. EBSCOhost, https://doi.org/10.1177/17588359241273062.

APA

Cho, D., Lord, S. J., Ward, R., IJzerman, M., Mitchell, A., Thomas, D. M., Cheyne, S., Martin, A., Morton, R. L., Simes, J., & Lee, C. K. (2024). Criteria for assessing evidence for biomarker-targeted therapies in rare cancers—an extrapolation framework. Therapeutic Advances in Medical Oncology, 1–20. https://doi.org/10.1177/17588359241273062

Chicago

Cho, Doah, Sarah J. Lord, Robyn Ward, Maarten IJzerman, Andrew Mitchell, David M. Thomas, Saskia Cheyne, et al. 2024. “Criteria for Assessing Evidence for Biomarker-Targeted Therapies in Rare Cancers—an Extrapolation Framework.” Therapeutic Advances in Medical Oncology, September, 1–20. doi:10.1177/17588359241273062.